Keywords: genzyme, 3rd-quarter, net, profit, falls, higher, costs
Genzyme's 3rd-quarter net profit falls 86% on higher costs, despite 14% sales hike
Article | 23 October 2006
USA-based biotechnology firm Genzyme says that, for the three months to September 30, 2006, its net income was $16.0 million, or $0.06 per diluted ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
